Table II. The Cox multivariate analysis of PFS revealed that for each unit increase in NLR there is a 14% increased risk of disease progression (p-value<0.0000001); furthermore, each 10% increase in PD-L1 reduces the risk of progression by 6.7% (p-value=0.022).

PFS: Progression-free survival; NSCLS NOS: non-small cell lung cancer not otherwise specified; PD-L1 TPS: Programmed death ligand 1 tumor proportion score; bNLR: basal neutrophil-to-lymphocytes ratio; bPLR: basal platelets-to-lymphocytes ratio. Bold values denote statistical significance.